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Objectives: To evaluate the in vitro activity of ceftolozane/tazobactam and other commonly used antipseudo-
monal antibiotics against geographically spread Pseudomonas aeruginosa isolates in the UK using disc suscepti-
bility testing.
Methods: The in vitro activity of ceftolozane/tazobactam and nine other commonly used antipseudomonal anti-
biotics was evaluated. Isolates were collected between January 2015 and April 2018. Susceptibility results were
interpreted using EUCAST 2018 criteria.
Results: Overall, 1326 clinical isolates from 14 centres in the UK were tested. The majority of the isolates were
collected from non-cystic fibrosis (non-CF) patients (n"1123, 85.0%). In addition, 199 cystic fibrosis (CF) isolates
were collected from 10 centres. Overall susceptibility to ceftolozane/tazobactam was 89.3% (n"1181), which
included 128 CF and 1053 non-CF isolates. The other antibacterial agents with the highest susceptibility were
tobramycin (92.4%, n"1221) and piperacillin/tazobactam (90.7%, n"1199). Susceptibility to all antibacterial
agents was lower for CF isolates. Piperacillin/tazobactam was the most active of the antibacterial agents tested,
followed by ceftolozane/tazobactam (70.4% and 64.3%, respectively), and ,60% of CF isolates were susceptible
to ceftazidime and the carbapenems. The reason for the higher rates of susceptibility to piperacillin/tazobactam
and lower susceptibility to ceftazidime compared with other studies is unclear.
Conclusions: The data presented here support the need to investigate the place of ceftolozane/tazobactam as a
treatment option in the management of pseudomonal infections, particularly in patients with CF. The results
highlight the importance of routine testing of new antibacterial agents and of making the data available to clini-
cians to make appropriate and informed treatment choices.
Introduction
Pseudomonas aeruginosa is an important pathogen of healthcare-
associated infections, including nosocomial pneumonia and urin-
ary tract and bloodstream infections. In a point prevalence study
conducted in ICUs in Western Europe, P. aeruginosa was one of the
most commonly reported pathogens, constituting 29% of all
Gram-negative isolates and present in 17% of all positive cultures.1
P. aeruginosa is also a clinically important, opportunistic pathogen
in patients with cystic fibrosis (CF), with infections often establish-
ing a pattern of persistence and strains undergoing a phenotypic
change characterized by the production of the polysaccharide al-
ginate.2 It has been estimated that more than 80% of CF patients
will succumb to respiratory failure caused by chronic bacterial in-
fection and concomitant airway inflammation.3 The intrinsic anti-
biotic resistance of P. aeruginosa and reported levels of acquired
resistance, including MDR strains, highlight the need for both sur-
veillance and novel antibacterial agents for the treatment of these
infections. The ECDC 2018 report documented that of the 16 885
invasive isolates of P. aeruginosa tested, 5201 (30.8%) were resist-
ant to a single antimicrobial group and 659 (3.9%) were resistant
to all five groups.4 A global priority pathogen list (PPL) ranking the
bacteria that pose the greatest threat to human health high-
lighted, in particular, Gram-negative bacteria that are resistant to
multiple antibiotics as high risk and identified carbapenem-
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resistant (CR) P. aeruginosa as a critical organism.5 These levels of
resistance and MDR trends present a therapeutic challenge,
particularly in patients receiving treatment on ICUs or with
comorbidities.6
Ceftolozane/tazobactam is a novel b-lactam/b-lactamase in-
hibitor combination with potent activity against Gram-negative
bacteria, particularly against P. aeruginosa, for which it is the most
active b-lactam antibiotic available.7 Ceftolozane/tazobactam has
been shown to be non-inferior to comparators in Phase III trials
investigating complicated intra-abdominal infection (cIAI),
complicated urinary tract infection (cUTI) and hospital-acquired
pneumonia (HAP), including ventilator-associated pneumonia
(VAP),8–10 with excellent in vitro activity against MDR and XDR
Pseudomonas spp.,6 including strains with derepressed AmpC or
up-regulated efflux.11 BSAC data in the UK report ceftolozane/
tazobactam as a potent antipseudomonal antibiotic in vitro,
with higher susceptibility rates than other b-lactam/b-lactamase
inhibitor combinations, carbapenems and fluoroquinolones.
Susceptibility rates have been consistently high over the 7 years
analysed (2011–17), with 99.5%, 99.5%, 100%, 100%, 100%,
99.4% and 99.5% bacteraemia isolates susceptible to ceftolozane/
tazobactam, respectively.12 For respiratory isolates, susceptibility
rates to ceftolozane/tazobactam were 98.1% for the 2015–16
period and 100% for the 2016–17 period.13
Data on the activity of ceftolozane/tazobactam against P. aeru-
ginosa were limited in the licensing trials. Despite the increasing
number of publications of in vitro studies,7,14–21 national and local
data are needed to guide informed prescribing and identify resist-
ance trends, treatment strategies and laboratory protocols.
Disc susceptibility testing is a well-established, easy-to-perform
and inexpensive methodology used in many laboratories as a
first-line test. Disc testing offers practical advantages over other
antimicrobial susceptibility testing methods for ceftolozane/tazo-
bactam, such as broth dilution or MIC gradient strips. It is versatile
in the range of antimicrobial agents that can be tested, requires
no special equipment and is inexpensive. Disc diffusion may be
the sole antimicrobial susceptibility testing method in diagnostic
microbiology laboratories where no automated alternatives are
available.
The purpose of the current study was to evaluate the in vitro
activity of ceftolozane/tazobactam and other commonly used
antipseudomonal antibiotics against geographically spread
P. aeruginosa isolates in the UK. A secondary objective was to pro-
vide centres with the opportunity to generate local susceptibility
data to guide appropriate antipseudomonal therapy.
Methods
Study setting and design
A multicentre, real-world study of clinically significant consecutive isolates
of P. aeruginosa collected across England, Scotland and Wales, including
isolates from CF patients, was conducted. A total of 14 diagnostic laborato-
ries were asked to collect 100 consecutive P. aeruginosa isolates that were
deemed clinically relevant from samples submitted to the laboratory over a
2 month period. If insufficient isolates were collected, then laboratories
could complete the 100 clinically relevant isolates from isolates stored for
clinical reasons. Isolates from the same patient were excluded from the
study.
Antimicrobial identification and susceptibility testing
MALDI-TOF MS methodology was used for species identification in the local
diagnostic laboratory. In vitro susceptibility testing following the EUCAST
disc diffusion methodology, with discs obtained from MAST Group Ltd, was
used to assess the susceptibility of P. aeruginosa isolates to ceftolozane/
tazobactam and nine other antipseudomonal antibiotics (piperacillin/tazo-
bactam, ceftazidime, imipenem, meropenem, aztreonam, amikacin, gen-
tamicin, tobramycin and ciprofloxacin). Mueller–Hinton agar was the
medium used for the disc diffusion methodology, as recommended by
EUCAST. Sites were allowed to use their preferred manufacturer. Disc diffu-
sion was selected as the preferred methodology for the study because of
its widespread use, convenience and reliability.22 Susceptibility results were
interpreted using EUCAST 2018 criteria.23
P. aeruginosa (ATCC 27853) and either Escherichia coli (ATCC 35218) or
Klebsiella pneumoniae (ATCC 700603) were used as the quality control
strains at every centre to monitor the performance of the tests. These con-
trol strains were tested daily whenever study isolates were analysed.
Internal quality control failure invalidated the results and required repeat
analysis.
The susceptibility of at least 10% of the isolates per centre was reas-
sessed at the Central Testing Laboratory for reproducibility and external
quality control on an isolate number exactly divisible by 10, in line with
United Kingdom Accreditation Service (UKAS) guidance. In addition, all iso-
lates with a zone diameter for ceftolozane/tazobactam within +1 mm of
the breakpoint (i.e. 23–25 mm), as per each referring centre’s susceptibility
testing results, was included in the robust external quality control study. All
testing in the Central Testing Laboratory was performed blind to previous
results and testing was performed in triplicate per isolate.
Isolates identified at the local laboratories using a methodology other
than MALDI-TOF MS (Bruker, Germany) were reidentified by MALDI-TOF MS
at the Central Testing Laboratory.
Statistical methods and analysis
The number of participating centres was made to reflect the BSAC
Resistance Surveillance Programme24 and provide a good geographical
spread across the UK. Consecutive isolates from each centre were required
by the protocol in order to reduce the risk of centres submitting isolates
from particular patients or sample types. A cap of 100 isolates, with no
more than 50% from CF patients per centre, was used to minimize sample
size variability across participant centres. No minimum number of CF iso-
lates was required from each centre.
Data were collected in an Excel spreadsheet with inhibition zone diam-
eter (mm) range limit for each antibiotic inhibition zone. A minimal dataset
of the following was collected for each isolate: date of sample, whether the
sample was from a CF patient, whether the isolate was phenotypically mu-
coid or non-mucoid, the source of the sample, the presumed source of the
infection and the specialty sending the sample. Centres were provided with
a list of sample sources, likely sites of infection and specialties.
The in vitro activity of ceftolozane/tazobactam and the nine other anti-
bacterial agents was expressed as inhibition zone diameter (mm) and sum-
marized for all isolates and by centre. The original zone size quoted by the
diagnostic laboratory was used in the analysis. Further analysis on the basis
of retesting isolates in the Central Testing Laboratory was based on a mean
of the zone diameters of the original and three repeat measures.
Percentages of susceptible and resistant isolates per antibiotic were calcu-
lated using EUCAST breakpoints23 and further analysed by antibiotic, ward,
sample source and CF/non-CF (patients without CF) isolates.
Ethics
Only bacterial isolates were included and analysed in the study. No human
tissue was collected, stored or analysed and no patient data were recorded,
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thus ethics approval was not applicable for this study. Health Research
Authority (HRA) approval was obtained.
Results
A total of 14 centres participated in the study, with the majority
being tertiary or teaching centres with large ICUs and CF units.
Isolates were collected from specimens submitted to the laborato-
ries between January 2015 and April 2018.
A total of 1326 isolates were included in the study. Twelve of
the sites contributed 100 isolates each. The remaining two sites
tested 69 and 57 isolates. MALDI-TOF MS identification confirmed
1322 (1123 non-CF and 199 CF) as P. aeruginosa. Other species
were Pseudomonas otitidis (n"2), Pseudomonas corrugata (n"1)
and Pseudomonas mosselii (n"1). The in vitro activities of ceftolo-
zane/tazobactam and nine comparators are summarized in
Table 1 for all of the 1322 P. aeruginosa isolates collected from
these 14 UK sites.
Of the isolates tested, 89.3% (n"1181) were susceptible to
ceftolozane/tazobactam, which included 128 CF and 1053 non-CF
isolates. The three antipseudomonals with the highest percentage
susceptibility were tobramycin (92.4%, n"1221), piperacillin/
tazobactam (90.7%, n"1199) and ceftolozane/tazobactam
(89.3%, n"1181). Figure 1 shows the distribution of zone diame-
ters (mm) for all 1322 P. aeruginosa isolates to ceftolozane/tazo-
bactam, piperacillin/tazobactam, ceftazidime and meropenem.
The majority of other antibacterial agents had lower susceptibility
rates and the single fluoroquinolone tested in this study, cipro-
floxacin, had an overall susceptibility rate of 73.6% (n"973).
Retesting in Central Testing Laboratory and
reproducibility
The three antipseudomonals with the highest percentage suscep-
tibility after retesting in the Central Testing Laboratory were again
tobramycin (92.7%, n"1226), ceftolozane/tazobactam (91.5%,
n"1209) and piperacillin/tazobactam (90.8%, n"1200) and
there were no statistical differences in susceptibility to these three
antibacterial agents. The reproducibility of the disc diameter
measurements varied between antibacterial agents tested
(Table 2). Ceftolozane/tazobactam had the lowest coefficient of
variation (4.8%) for disc diameter, along with imipenem (6.8%),
amikacin (7.3%), tobramycin (5.3%) and ciprofloxacin (6.9%).
Isolates from non-CF and CF patients
The majority of the total isolates were collected from non-CF
patients (n"1123, 85.0%) and susceptibility was consistent with
the overall results. Tobramycin, piperacillin/tazobactam and cefto-
lozane/tazobactam were the three most active antibacterial
agents against all non-CF isolates, with susceptibilities of 97.0%,
94.3% and 93.8%, respectively. In line with the overall results, no
isolates were susceptible to aztreonam (Figure S1, available as
Supplementary data at JAC-AMR Online).
A total of 199 CF isolates were collected from 10 centres, with
148 isolates (74.4%) originating from respiratory wards and the
remaining isolates obtained from a ward unknown to the investiga-
tors. Sputum was the primary sample source (n"176, 88.4%), with
the most likely site of infection being the lower respiratory tract
(n"195, 98.0%). Overall, susceptibility to all antibacterial agents
Table 1. Susceptibility of P. aeruginosa isolates, including those from patients with CF
C/T TZP CAZ IPM MEM ATM AMK GEN TOB CIP
Overall (n"1322)
SUS, n 1181 1199 1051 1090 1050 0 1145 1121 1221 973
% 89.3 90.7 79.5 82.5 79.4 0 86.6 84.8 92.4 73.6
INT, n — — — 38 81 1136 73 — — —
% 2.9 6.1 85.9 5.5
RES, n 141 123 271 194 191 186 104 201 101 349
% 10.7 9.3 20.5 14.7 14.4 14.1 7.9 15.2 7.6 26.4
CF (n"199)
SUS, n 128 140 95 105 105 0 97 103 132 70
% 64.3 70.4 47.7 52.8 52.8 48.7 51.8 66.3 35.2
INT, n — — — 7 13 129 23 — — —
% 3.5 6.5 64.8 11.6
RES, n 71 59 104 87 81 70 79 96 67 129
% 35.7 29.6 52.3 43.7 40.7 35.2 39.7 48.2 33.7 64.8
Non-CF (n"1123)
SUS, n 1053 1059 956 985 945 0 1048 1018 1089 903
% 93.8 94.3 85.1 87.7 84.1 93.3 90.7 97.0 80.4
INT, n — — — 31 68 1007 50 — — —
% 2.8 6.5 89.7 4.5
RES, n 70 64 167 107 110 116 25 105 34 220
% 6.2 5.7 14.9 9.5 9.8 10.3 2.2 9.3 3.0 19.6
— indicates that there is no gap between susceptible and resistant zone diameters.
C/T, ceftolozane/tazobactam; TZP, piperacillin/tazobactam; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; ATM, aztreonam; AMK, amikacin;
GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; INT, intermediate; RES, resistant; SUS, susceptible.
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was lower in comparison with non-CF isolates (Table 1). Piperacillin/
tazobactam was the most active of the antibacterial agents tested,
followed by ceftolozane/tazobactam (70.4% and 64.3%, respect-
ively). Over 40% of CF isolates were resistant to ceftazidime and the
carbapenems (ceftazidime 52.3%, imipenem 43.7% and merope-
nem 40.7%). Tobramycin was the only aminoglycoside that showed
in vitro activity .55%, with susceptibility rates of 66.3% (Figure S2).
Type of ward
Isolates were collected from multiple wards at each centre, with
the majority coming from respiratory wards (n"220, 16.6%), ICUs
(n"151, 11.4%) and acute medical wards (n"144, 10.9%) (Table
S1). Susceptibility rates for ceftolozane/tazobactam ranged from
71.8% (respiratory wards, n"220) to 100% (nephrology wards,
n"33). Isolates collected from respiratory wards showed the
lowest susceptibility to all antibacterial agents but were generally
more susceptible to b-lactams (58.2% to 76.0%), gentamicin
(61.4%) and tobramycin (74.1%). Aminoglycosides were the most
active class against isolates collected from ICUs (tobramycin
94.0%, amikacin 94.7% and gentamicin 91.4%, respectively).
Sample source
Samples were collected from various sources [sputum (n" 420),
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Figure 1. Distribution of zone diameters (mm) for all 1322 P. aeruginosa isolates to ceftolozane/tazobactam, piperacillin/tazobactam, ceftazidime,
meropenem, imipenem and ciprofloxacin. EUCAST 2018 breakpoints are included for each antibiotic and marked on the figure.
Table 2. Coefficient of variation of zone size diameter as retested three times by Central Testing Laboratory
C/T TZP CAZ IPM MEM ATM AMK GEN TOB CIP
N 143 143 143 143 143 143 143 143 143 143
Coefficient
of variation (%)
4.8 10.3 27.0 6.8 17.1 15.6 7.8 9.4 5.3 6.9
C/T, ceftolozane/tazobactam; TZP, piperacillin/tazobactam; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; ATM, aztreonam; AMK, amikacin;
GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin.
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(n"31), bronchoalveolar lavage (BAL) (n"20), CSF (n"5) and
other (n"156)]. Rates of susceptibility to ceftolozane/tazobactam
of isolates from blood, wound swab and urine samples were 96.8%,
95.3% and 91.7%, respectively. Susceptibility of all sputum isolates,
including those from patients with CF, was 79.3%. Of the other
b-lactams tested, piperacillin/tazobactam was the most active
across all sample sources and susceptibility ranged from 82.9% for
sputum samples to 100% for CSF samples. The susceptibility to
ceftazidime and the carbapenems was lower compared with
ceftolozane/tazobactam and piperacillin/tazobactam across all
sample sources. More than 90% of isolates from blood cultures, pus
and wound swabs were reported as susceptible to the three
aminoglycosides tested. As with b-lactams, susceptibility rates to
aminoglycosides in sputum were generally lower (amikacin 72.1%,
gentamicin 72.9% and tobramycin 83.6%). The monobactam az-
treonam and the fluoroquinolone ciprofloxacin were the least active
antibacterial agents across all sample sources (Table 3).
Site of infection
Sites of infection from which isolates were collected included lower
respiratory tract (n"481, 36.4%), urinary tract (n"245, 18.5%),
skin and soft tissue (n"214, 16.2%), intra-abdominal (n"60,
4.5%), burns (n"22, 1.7%), prosthetic joints (n"17, 1.3%), CNS
(n"5, 0.4%) and other sites (n"278, 21.0%). Susceptibility to cef-
tolozane/tazobactam ranged between 80.9%, for lower respiratory
tract infections, to 100% for CNS; however, CNS isolates were very
limited (n"5). Susceptibility to ceftolozane/tazobactam in UTI
isolates was high (92.2%) but lower than in skin and soft tissue
infections (96.3%). Isolates from lower respiratory tract infections
had the lowest rates of susceptibility to all antibacterial agents
tested, with values ranging from 60.7% for ciprofloxacin to 84.8%
for tobramycin. (Details of the sites of infection and susceptibilities
to the other antibacterial agents tested can be found in Table S2).
Discussion
P. aeruginosa is ubiquitous in aquatic environments and difficult to
eradicate because of both its versatility and intrinsic tolerance to
many detergents, disinfectants and antimicrobial agents.25
In addition, increasing levels of resistance and MDR strains,
particularly in ICUs, highlights the need for new, effective agents
for treatment.26 This is a large comparative study showing the sus-
ceptibility to ceftolozane/tazobactam and commonly used anti-
pseudomonal antibiotics across the UK.
The findings reported here confirm the activity of ceftolozane/
tazobactam, with an overall susceptibility rate of 89.3% and a sus-
ceptibility rate of 88.1% for isolates obtained from ICUs. Most of
the data are consistent with proportions of isolates susceptible to
ceftolozane/tazobactam reported elsewhere. For example, the
bacteraemia data for ceftolozane/tazobactam in this study (97%
of blood isolates being susceptible to ceftolozane/tazobactam) are
consistent with data from the BSAC Resistance Surveillance
Programme and UK national reference laboratory surveillance
data collected between 2011 and 2017, which reported 99.4% to
100% of isolates as susceptible to ceftolozane/tazobactam.12
In the current study, of the 20 isolates obtained from BAL sam-
ples and the 420 from sputum, susceptibility to ceftolozane/tazo-
bactam was 80.0% and 79.3%, respectively. These susceptibility
rates are lower than those reported by BSAC for the periods
2015–16 (98.1%) and 2016–17 (100%), respectively,13 although it
should be noted that the BSAC Resistance Surveillance Programme
excludes isolates from CF patients.
Susceptibility rates for other commonly used antibacterial
agents for the treatment of pseudomonal infections were also
high; ceftolozane/tazobactam remained more active in vitro in the
BSAC study than other b-lactams, b-lactam/b-lactamase inhibitor
combinations, carbapenems, aminoglycosides and fluoroquino-
lones. Susceptibility to ceftolozane/tazobactam of sputum isolates
was lower in the current study (79.3%). However, 42% of these
isolates came from CF patients, where susceptibility rates to
all antibacterial agents were predictably lower. The high percent-
age susceptibility to ceftolozane/tazobactam and tobramycin was
anticipated, although piperacillin/tazobactam susceptibility
rates were higher than those reported in some other studies,
including the BSAC Resistance Surveillance Programme.13
Interestingly, recent data from the BSAC Resistance Surveillance
Programme showed a decline in the rate of resistance to piperacil-
lin/tazobactam, with 97.6% of P. aeruginosa isolates from blood in
2017 and 90.6% of respiratory isolates collected between 2016
and 2017 being susceptible to piperacillin/tazobactam (http://
Table 3. Susceptibility of isolates to all antibacterial agents per sample source (%) (n"1322)
Sample
source N
C/T TZP CAZ IPM MEM ATM AMK GEN TOB CIP
S% R% S% R% S% R% S% I% R% S% I% R% S% I% R% S% I% R% S% R% S% R% S% R%
Blood 251 96.8 3.3 94.0 6.0 82.9 17.1 88.8 4.0 7.2 84.5 7.6 8.0 0 90.4 9.6 96.0 1.6 2.4 93.2 6.8 94.4 5.6 81.7 18.3
BAL 20 80.0 25.0 85.0 15.0 85.0 15.0 85.0 0 15.0 80.0 5.0 15.0 0 85.0 15.0 95.0 0 5.0 90.0 10.0 95.0 5.0 95.0 5.0
Sputum 420 79.3 26.1 82.9 17.1 66.7 33.3 71.0 2.9 26.2 68.3 6.4 25.2 0 77.9 22.1 72.1 8.1 19.8 72.9 27.1 83.6 16.4 57.4 42.6
CSF 5 100 0 100 0 100 0 80.0 0 20.0 80.0 0 20.0 0 80.0 20.0 100 0 0 100 0 100 0 100 0
Urine 204 91.7 9.1 96.1 3.9 83.3 16.7 89.7 3.4 6.9 86.3 5.9 7.8 0 89.7 10.3 86.3 11.8 2.0 82.8 17.2 97.5 2.5 75.0 25.0
Pus 31 83.9 19.2 93.5 6.5 83.9 16.1 93.5 3.2 3.2 90.3 6.5 3.2 0 87.1 12.9 100 0 0 100 0 100 0 90.3 9.7
Wound
swab
235 95.3 4.9 94.0 6.0 89.4 10.6 86.4 3.0 10.6 84.3 4.3 11.5 0 90.2 9.8 95.3 3.4 1.3 91.9 8.1 97.0 3.0 83.8 16.2
Other 156 94.2 6.1 94.2 5.8 86.5 13.5 85.3 0.6 14.1 82.7 6.4 10.9 0 89.1 10.9 93.6 1.9 4.5 91.0 9.0 96.8 3.2 80.1 19.9
C/T, ceftolozane/tazobactam; TZP, piperacillin/tazobactam; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; ATM, aztreonam; AMK, amikacin;
GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; I, intermediate; R, resistant; S, susceptible.
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www.bsacsurv.org/reports/bacteraemia#results). However, bac-
teraemia data from PHE reported a decline in susceptibility to
piperacillin/tazobactam from 91% in 2015 to 86% in 201727 and
further longitudinal data are needed to interpret the significance
of these conflicting trends. Sader et al.28 reported overall suscepti-
bility of Pseudomonas spp. to piperacillin/tazobactam in the USA in
2017 as 77.5% and an Australian study of blood isolates reported
an overall susceptibility of 67% for blood isolates collected over a
10 year period (2008 to 2018).29 It is important to consider that it
is difficult to compare the findings of the current study, which used
disc diffusion methodology, with those of international studies
that employed MIC CLSI methodology.
Unexpectedly low susceptibility rates to ceftazidime were seen
in the current study (overall 79.5%; non-CF isolates 85.1%) when
compared with those reported by BSAC (98.1% for the 2017 bac-
teraemia isolates and 94.6% for the 2016–17 respiratory isolates).
This observation was particularly evident for the blood isolates,
where the susceptibility rate for ceftazidime in the current study
was 82.9%. The 2017 data from PHE bacteraemia isolates also
reported higher susceptibility rates of 93% for ceftazidime.27 In the
current study, ceftazidime susceptibility for respiratory isolates
was 68.2%, compared with 94.6% for the 2016–17 BSAC respira-
tory isolates. The latter finding may, in part, be explained by the in-
clusion of CF isolates in the respiratory samples collected in the
study.
The recent introduction by EUCAST of an area of technical un-
certainty (ATU) of 18–19 mm for piperacillin/tazobactam,30 where
interpretation of results from disc diffusion is uncertain, may help
explain the differences reported in the current study, where use of
the 2018 EUCAST criteria23 may have overestimated the number
of susceptible isolates. Although this clearly warrants further inves-
tigation, it is outside the scope of the current study. The 2015 data
from the EARSS surveillance database reported a range of suscep-
tibilities to piperacillin/tazobactam, from 100% (Iceland and
Luxembourg) to 43% (Romania).25 Data from the USA collected
between 2012 and 2015 reported overall susceptibilities of 97% to
ceftolozane/tazobactam and 80% to piperacillin/tazobactam.7
Nearly half of the CF isolates were non-susceptible to ceftazidime
and the carbapenems (ceftazidime 52.3%, imipenem 47.2% and
meropenem 47.2%). Tobramycin was the only aminoglycoside
that showed in vitro activity above 55%, with susceptibility rates
(66.3%) similar to those of ceftolozane/tazobactam. Of all the anti-
bacterial agents included in the study, tobramycin had the highest
in vitro susceptibility rates for CF and non-CF isolates: 66.3% and
97.0%, respectively.
As stated previously, the reason for the higher rates of sus-
ceptibility to piperacillin/tazobactam and lower susceptibility to
ceftazidime recorded in the current study compared with other
studies is unclear and further investigation is needed, especially as
ceftazidime remains one of the recommended treatments for
the management of pseudomonal infections, as described in
the Joint Working Party (JWP) MDR Gram-negative guidelines.31
The JWP guidelines highlight ceftazidime resistance as pivotal in
demonstrating the need for new antibacterial agents, such as
ceftolozane/tazobactam, rather than the WHO position, which
identifies CR P. aeruginosa, because most resistance to carbape-
nems is characterized by porin loss and efflux mechanisms.32
The use of disc susceptibility testing is confirmed as useful in
this study, given the coefficients of variation of zone size diameter
seen, with the exception of ceftazidime. The absolute necessity for
local susceptibility data and the cheapness, speed and simplicity
of disc testing further support its use.
Limitations of the study are that there may have been variation
in which isolates were considered clinically significant, though it
seems unlikely this would account for the differences in suscepti-
bilities reported here. For practicality, disc susceptibility testing was
used for the samples, whereas broth dilution is the reference
standard for determination of antibiotic susceptibility, particularly
as colistin susceptibility cannot be tested with disc methodology.
The already noted reproducibility of disc zone diameters and
agreement with previously reported results is supportive of using
disc diffusion methodology.
Although ceftolozane/tazobactam has been approved only for
the treatment of cUTI, cIAI and HAP/VAP, it has become a suitable
and attractive option for the treatment of MDR or XDR P. aerugi-
nosa.33 A prospective observational study of 58 patients receiving
ceftolozane/tazobactam monotherapy (n"21, 36.2%) or combin-
ation therapy for 72 h (n"37, 63.8%) reported a clinical cure in
37 patients (63.8%) and resistance development in 8 (13.8%).34
Other recent reports include the clinical use of ceftolozane/tazo-
bactam in patients with osteomyelitis and skin and soft tissue
infections35 and haematologic malignancies and transplant
recipients.36
The data presented here support the need to investigate the
place of ceftolozane/tazobactam as an effective treatment option
in the management of pseudomonal infections, particularly in
patients with CF. In addition, further studies are needed to address
the omission of colistin from the current study. The results pre-
sented here highlight the importance of routine testing of new
antibacterial agents and of making the data available to clinicians
to make appropriate and informed treatment choices.
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